西妥昔单抗或度伐利尤单抗联合放疗用于顺铂禁忌的局部晚期头颈癌患者(NRG-HN004):一项开放标签、多中心、平行组、随机2/3期试验
NRG-HN004研究在顺铂禁忌的局部晚期头颈鳞癌患者中比较放疗联合度伐利尤单抗与联合西妥昔单抗的疗效。2期部分随机分配186例患者(度伐利尤单抗123例,西妥昔单抗63例),2年无进展生存率分别为50.6%和63.7%(HR 1.33,95%CI 0.84-2.12;p=0.89),因无效性分析提前终止,3期部分未进行。
要点
- 在顺铂禁忌的局部晚期头颈鳞癌中,度伐利尤单抗联合放疗较西妥昔单抗联合放疗未改善无进展生存。
- 2年无进展生存率:度伐利尤单抗组50.6% vs 西妥昔单抗组63.7%(HR 1.33,95%CI 0.84-2.12)。
- 两组不良事件相似,常见3-4级不良事件为吞咽困难、淋巴细胞减少和口腔黏膜炎。
核心结论
- 研究结果提示,在顺铂禁忌的头颈鳞癌患者中,度伐利尤单抗联合放疗较西妥昔单抗联合放疗未改善结局。
研究设计与样本
- NRG-HN004为开放标签、多中心、平行组、随机2/3期试验,含安全性导入期,在北美89个学术和社区医疗中心开展。
- 纳入年龄≥18岁、美国癌症联合委员会第8版III-IVB期p16阴性头颈鳞癌或不良I-III期p16阳性口咽癌或原发灶不明癌、且存在顺铂禁忌证的患者。
- 患者按2:1随机分配至度伐利尤单抗组(123例)或西妥昔单抗组(63例),均接受调强放疗(70 Gy/35次/7周)。
- 度伐利尤单抗用法:放疗前2周开始静脉1500 mg,放疗第2周起每4周一次,共7周期;西妥昔单抗用法:放疗前1周静脉400 mg/m2,放疗第1周起每周250 mg/m2,共8周期。
- 2期主要终点为意向治疗人群的无进展生存期,预设50%信息量时进行无效性分析。
主要发现
- 中位随访2.3年(IQR 1.9-3.1)时,2年无进展生存率度伐利尤单抗组为50.6%(95%CI 41.5-59.8),西妥昔单抗组为63.7%(95%CI 51.3-76.1),HR 1.33(95%CI 0.84-2.12),p=0.89。
- 3-4级不良事件:吞咽困难度伐利尤单抗组26/119例(22%) vs 西妥昔单抗组18/61例(30%);淋巴细胞减少33例(28%) vs 20例(33%);口腔黏膜炎13例(11%) vs 11例(18%)。
- 治疗相关不良事件死亡:度伐利尤单抗组4例(3%),西妥昔单抗组1例(2%)。
关键数值与推荐
- 2期预设无效性分析显示HR≥1.0( favouring西妥昔单抗)时考虑提前终止,实际HR为1.33(95%CI 0.84-2.12)。
- 2年无进展生存率度伐利尤单抗组50.6%(95%CI 41.5-59.8) vs 西妥昔单抗组63.7%(95%CI 51.3-76.1)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 2期入组于2021年7月30日因无效性分析暂停,并于2022年9月1日永久关闭,3期部分未进行。
- 原文结论指出需要进一步试验来定义该人群的标准治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Management of patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) when cisplatin is contraindicated is controversial. We aimed to assess whether radiotherapy with concurrent and adjuvant durvalumab would improve outcomes compared with radiotherapy with cetuximab. METHODS: NRG-HN004 was designed as an open-label, multicentre, parallel-group, randomised, phase 2/3 trial with safety lead-in conducted at 89 academic and community medical centres in North America. Eligible patients were aged 18 years or older with American Joint Committee on Cancer 8th edition stage III-IVB p16-negative HNSCC or unfavourable stage I-III p16-positive oropharyngeal or unknown primary carcinoma, who had a contraindication to cisplatin (Eastern Cooperative Oncology Group [ECOG] performance status 2, renal or hearing impairment, peripheral neuropathy, aged at least 70 years with moderate or severe comorbidity, or aged younger than 70 years with severe comorbidity). Patients were randomly assigned (2:1) by permuted block randomisation (multiples of 6) to intravenous durvalumab 1500 mg starting 2 weeks before radiotherapy then every 4 weeks starting week 2 of radiotherapy (seven cycles) or intravenous cetuximab 400 mg/m2 1 week before radiotherapy then 250 mg/m2 weekly beginning week 1 of radiotherapy (eight cycles), with intensity-modulated radiotherapy (70 Gy in 35 fractions over 7 weeks). Stratification factors were tumour and nodal stage, ECOG performance status and comorbidity, and primary site and p16 status. The phase 2 primary endpoint was progression-free survival in the intention-to-treat population. There was one prespecified interim futility analysis at 50% of progression-free survival information. If the observed hazard ratio was 1·0 or more, favouring cetuximab, early stopping would be considered. Extended follow-up analysis was post hoc. This trial is registered with ClinicalTrials.gov, NCT03258554, and is closed to enrolment. FINDINGS: Following a ten-patient safety lead-in, the phase 2 trial enrolled 190 patients from March 12, 2019, to July 30, 2021, 186 of whom were randomly assigned (123 to durvalumab and 63 to cetuximab). Median age was 72 years (IQR 64-77), 30 (16%) patients were women and 156 (84%) were men. Phase 2 accrual was suspended in July 30, 2021, following an interim futility analysis, and permanently closed in Sept 1, 2022. The phase 3 part of the trial was not conducted. At a median follow-up of 2·3 years (IQR 1·9-3·1) for the extended follow-up (data cutoff July 31, 2023; post-hoc analysis), 2-year progression-free survival was 50·6% (95% CI 41·5-59·8) in the durvalumab group versus 63·7% (51·3-76·1) in the cetuximab group (hazard ratio 1·33 [95% CI 0·84-2·12]; p=0·89). Adverse events were similar in both groups. The most common grade 3-4 adverse events were dysphagia (26 [22%] of 119 patients in the durvalumab group vs 18 [30%] of 61 patients in the cetuximab group), lymphopenia (33 [28%] vs 20 [33%]), and oral mucositis (13 [11%] vs 11 [18%]). Four (3%) patients in the durvalumab group and one (2%) in the cetuximab group died from treatment-related adverse events (death not otherwise specified, laryngeal oedema, lung infection, and respiratory failure in the durvalumab group and sudden death not otherwise specified in the cetuximab group). INTERPRETATION: Our findings suggest that durvalumab did not improve outcomes compared with cetuximab in patients with HNSCC with contraindications to cisplatin. Further trials are needed to define the standard of care for this population. FUNDING: US National Cancer Institute and AstraZeneca.
引用
- Mell LK, Torres-Saavedra PA, Wong SJ, et al. Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial. Lancet Oncol. 2024. PMID: 39551064. doi:10.1016/S1470-2045(24)00507-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。